CN101411829A - Chinese medicinal composition for treating megrims and formulation thereof - Google Patents
Chinese medicinal composition for treating megrims and formulation thereof Download PDFInfo
- Publication number
- CN101411829A CN101411829A CNA2007101632070A CN200710163207A CN101411829A CN 101411829 A CN101411829 A CN 101411829A CN A2007101632070 A CNA2007101632070 A CN A2007101632070A CN 200710163207 A CN200710163207 A CN 200710163207A CN 101411829 A CN101411829 A CN 101411829A
- Authority
- CN
- China
- Prior art keywords
- vertigo
- chinese medicine
- medicine composition
- traditional chinese
- leech
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种治疗眩晕症的中药组合物及其制剂。本发明药物由黄芪、水蛭、全蝎等十二味原料药组成，诸药合用，共奏补虚通络，搜风化痰，定眩益髓之功。临床研究显示，本发明中药组合物可有效治疗眩晕症。The invention provides a traditional Chinese medicine composition for treating vertigo and its preparation. The medicine of the present invention is composed of 12 raw materials such as astragalus, leech, and scorpion. All medicines are combined to play the functions of tonifying deficiency and dredging collaterals, searching wind and eliminating phlegm, calming dizziness and benefiting marrow. Clinical research shows that the traditional Chinese medicine composition of the invention can effectively treat vertigo.
Description
技术领域 technical field
本发明涉及一种治疗眩晕症的中药组合物及其制剂，属于中草药制剂技术领域。The invention relates to a traditional Chinese medicine composition for treating vertigo and a preparation thereof, belonging to the technical field of Chinese herbal medicine preparations.
背景技术 Background technique
眩晕症是常见的临床综合症，随着人口老龄化，发病率日益增高，受到国内外医务界广泛重视，占内科急诊病人的5％，老年门诊的81-91％(张素珍.眩晕症的诊断与治疗.人民军医出版社，2001：1-2；116-120；238-240)，神经科和急诊科就诊的患者病因以椎-基底动脉供血不足最为常见。该病主要与动脉硬化、血流动力学改变及颈椎病密切相关，其基本病理变化为椎-基底动脉血液循环障碍而造成局部脑组织，尤其是平衡器官供血不足(孙岩，陈眉，黄晓明等.醒脑静注射液为主治疗椎-基底动脉供血不足46例.浙江中医学院学报，2000，24(2)：28-29)。Vertigo is a common clinical syndrome. With the aging of the population, the incidence rate is increasing day by day. It is widely valued by the medical circles at home and abroad, accounting for 5% of internal medicine emergency patients and 81-91% of geriatric outpatients (Zhang Suzhen. The diagnosis of vertigo and treatment. People's Military Medical Publishing House, 2001: 1-2; 116-120; 238-240), the most common etiology of patients in neurology and emergency departments is vertebral-basilar artery insufficiency. The disease is mainly closely related to arteriosclerosis, hemodynamic changes and cervical spondylosis, and its basic pathological change is that vertebral-basilar artery blood circulation disorder causes insufficient blood supply to local brain tissue, especially balance organs (Sun Yan, Chen Mei, Huang Xiaoming etc. Xingnaojing Injection mainly treated 46 cases of vertebral-basilar artery insufficiency. Journal of Zhejiang University of Traditional Chinese Medicine, 2000, 24(2): 28-29).
眩晕症属中医眩晕范畴，其病机复杂，但归纳起来不外风、火、痰、虚四个方面，继而有“无痰不作眩”、“无虚不作眩”、“无风不作眩”的论述，然而在临床中发现病变过程中常有脉络瘀阻的病理现象，辩证治疗中酌加通络药物，往往收到事半功倍之疗效，认为眩晕的病机为肝肾不足，气虚衰弱脑络失荣，加之脉络空虚，卫外不固，风痰之邪，乘虚入络致脉络瘀阻，闭阻气血，从而出现眩晕症候，治疗当以补虚通络为主要治疗原则，并以祛风化痰为佐。Vertigo belongs to the category of vertigo in traditional Chinese medicine. Its pathogenesis is complicated, but it can be summed up in four aspects: wind, fire, phlegm, and deficiency. However, it is found in the clinic that there is often a pathological phenomenon of collateral stasis in the course of the lesion. Adding collateral dredging drugs in the dialectical treatment often achieves twice the result with half the effort. It is believed that the pathogenesis of vertigo is liver and kidney deficiency, qi deficiency and brain collateral loss Rong, coupled with the emptiness of the veins, weak defenses outside the body, and the evil of wind and phlegm, taking advantage of the deficiency and entering the collaterals, causing blood stasis in the collaterals, blocking Qi and blood, and resulting in dizziness. Phlegm is the assistant.
眩晕是一种运动性或感觉性幻觉，是机体对空间定位和重力关系体查能力的障碍，呈旋转感、摇摆感或漂浮感，主要由迷路、前庭神经、脑干及小脑病变引起。多见于中老年人，临床上一般分为周围性眩晕和中枢性眩晕两种类型，其中椎-基底动脉供血不足(包括小脑的动脉、内听动脉、脑桥动脉、大脑后动脉缺血)是中枢性眩晕的常见病因。通过临床研究发现，本发明药物对于治疗由椎-基底动脉供血不足引起的眩晕症，临床效果显著，不仅能迅速控制症状，而且能预防复发。Vertigo is a motor or sensory hallucination. It is an obstacle to the body's ability to detect spatial orientation and gravity. It presents a sense of rotation, swing or floating. It is mainly caused by lesions of the labyrinth, vestibular nerve, brainstem and cerebellum. It is more common in middle-aged and elderly people. It is generally divided into two types: peripheral vertigo and central vertigo clinically. Insufficient blood supply of the vertebral basilar artery (including cerebellar arteries, internal auditory arteries, pontine arteries, and posterior cerebral artery ischemia) is the central vertigo. Common causes of vertigo. It is found through clinical research that the medicament of the present invention has remarkable clinical effect on the treatment of vertigo caused by vertebra-basilar artery insufficiency, not only can control the symptoms rapidly, but also can prevent recurrence.
发明内容 Contents of the invention
本发明提供了一种治疗眩晕症的中药组合物及其制剂。The invention provides a traditional Chinese medicine composition for treating vertigo and its preparation.
本发明药物中黄芪、水蛭益气通络为君药；川芎、全蝎、当归、山茱萸活血通络为臣药，其中川芎活血祛风，上行头目，为血中之气药，全蝎搜风通络，当归补血和血，山茱萸补血滋阴，益髓添精，君臣相合，共奏益气活血通络之功；白术、茯苓、陈皮、竹茹健脾除湿化痰，治生痰之本，怀牛膝补益肝肾，助补血添精之力，共为佐药；石菖蒲引药上行以通脑络，开清窍为使药，诸药合用，共奏补虚通络，搜风化痰，定眩益髓之功。Among the medicines of the present invention, astragalus and leech are the monarch drugs; Chuanxiong, Scorpion, Angelica, and Cornus officinalis are ministerial drugs, among which Chuanxiong promotes blood circulation and dispels wind, and the ascending leader is the Qi medicine in the blood. Tongluo, Angelica nourishes blood and blood, Cornus officinalis nourishes blood and nourishes yin, nourishes marrow and adds essence, the monarch and his ministers work together to benefit qi, activate blood and dredge collaterals; , Huai Achyranthes bidentata nourishes the liver and kidney, helps to nourish blood and replenish essence, and is an adjuvant drug; Shichangpu introduces medicines to unblock the brain and open the clear orifices as the envoy medicine, and all medicines are used in combination to play the role of tonifying the deficiency and dredging the collaterals, and searching for weathering Phlegm, the function of calming dizziness and benefiting marrow.
本发明提供一种治疗眩晕症的中药组合物，其特征在于是由如下重量份比例的原料药制成的：The invention provides a Chinese medicine composition for treating vertigo, which is characterized in that it is made of the following raw materials in parts by weight:
黄芪 30-50 水蛭 2-5 全蝎 2-5 川芎 6-12Astragalus 30-50 Leech 2-5 Scorpion 2-5 Chuanxiong 6-12
山茱萸 6-12 怀牛膝 6-15 白术 6-15 茯苓 12-40Cornus officinalis 6-12 Achyranthes bidentata 6-15 Atractylodes macrocephala 6-15 Poria cocos 12-40
陈皮 6-12 竹茹 6-12 当归 6-15 石菖蒲 5-10Chenpi 6-12 Bamboo Ru 6-12 Angelica 6-15 Shichangpu 5-10
优选地，本发明中药组合物，是由如下重量份比例的原料药制成的：Preferably, the traditional Chinese medicine composition of the present invention is made of the following raw materials in parts by weight:
黄芪 35-45 水蛭 2-5 全蝎 2-5 川芎 7-10Astragalus 35-45 Leech 2-5 Scorpion 2-5 Chuanxiong 7-10
山茱萸 7-10 怀牛膝 8-13 白术 8-14 茯苓 18-35Cornus officinalis 7-10 Achyranthes bidentata 8-13 Atractylodes macrocephala 8-14 Poria cocos 18-35
陈皮 7-11 竹茹 6-12 当归 6-13 石菖蒲 5-10Tangerine peel 7-11 Bamboo Ru 6-12 Angelica 6-13 Shichangpu 5-10
更优选地，本发明中药组合物是由如下重量份比例的原料药制成的：More preferably, the traditional Chinese medicine composition of the present invention is made of the following raw materials in parts by weight:
黄芪 32 水蛭 2.5 全蝎 2.5 川芎 7Astragalus 32 Leech 2.5 Scorpion 2.5 Chuanxiong 7
山茱萸 7 怀牛膝 7 白术 7 茯苓 15Dogwood 7 Achyranthes bidentata 7 Atractylodes macrocephala 7 Poria cocos 15
陈皮 6.5 竹茹 6.5 当归 7 石菖蒲 6Chenpi 6.5 Bamboo Ru 6.5 Angelica 7 Shichangpu 6
或由如下重量份比例的原料药制成的：Or made from the crude drug in the following parts by weight ratio:
黄芪 48 水蛭 4.5 全蝎 4.5 川芎 11Astragalus 48 Leech 4.5 Scorpion 4.5 Chuanxiong 11
山茱萸 11 怀牛膝 14 白术 14 茯苓 38Dogwood 11 Achyranthes bidentata 14 Atractylodes macrocephala 14 Poria cocos 38
陈皮 10.5 竹茹 11.5 当归 13.5 石菖蒲 9Chenpi 10.5 Bamboo Ru 11.5 Angelica 13.5 Shichangpu 9
或由如下重量份比例的原料药制成的：Or made from the crude drug in the following parts by weight ratio:
黄芪 34 水蛭 5 全蝎 2.5 川芎 11.5Astragalus 34 Leech 5 Scorpion 2.5 Chuanxiong 11.5
山茱萸 6.5 怀牛膝 14 白术 7 茯苓 37Dogwood 6.5 Achyranthes bidentata 14 Atractylodes macrocephala 7 Poria cocos 37
陈皮 6.5 竹茹 11 当归 7 石菖蒲 8.5Chenpi 6.5 Bamboo Ru 11 Angelica 7 Shichangpu 8.5
或由如下重量份比例的原料药制成的：Or made from the crude drug in the following parts by weight ratio:
黄芪 40 水蛭 3.5 全蝎 3.5 川芎 9Astragalus 40 Leech 3.5 Scorpion 3.5 Chuanxiong 9
山茱萸 9 怀牛膝 10.5 白术 10 茯苓 25Dogwood 9 Achyranthes bidentata 10.5 Atractylodes macrocephala 10 Poria cocos 25
陈皮 9 竹茹 9 当归 10.5 石菖蒲 7.5Tangerine peel 9 Bamboo Ru 9 Angelica 10.5 Shichangpu 7.5
本发明中药组合物的制剂剂型为汤剂、散剂、胶囊剂、丸剂或口服液。The dosage form of the traditional Chinese medicine composition of the present invention is decoction, powder, capsule, pill or oral liquid.
本发明中药组合物的剂型采用常规的制备方法制备，例如，范碧亭《中药药剂学》(上海科学出版社1997年12月第1版)记载的制备工艺，制成药剂学可接受的常规剂型。The dosage form of the Chinese medicine composition of the present invention is prepared by a conventional preparation method, for example, the preparation process recorded in Fan Biting's "Chinese Medicine Pharmaceutics" (Shanghai Science Press, December 1997, 1st edition), to make a pharmaceutically acceptable conventional dosage form.
本发明的应用中，所述中药组合物为汤剂、散剂、胶囊剂、丸剂或口服液制剂中的一种，为使上述剂型能够实现，需在制备这些剂型时加入药学可接受的辅料，例如：填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质等。填充剂包括：淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等；崩解剂包括：淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素钠等；润滑剂包括：硬脂酸镁、十二烷基硫酸钠、滑石粉、二氧化硅等；助悬剂包括：聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等；粘合剂包括，淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等；甜味剂包括：糖精钠、阿斯帕坦、蔗糖、甜蜜素、甘草次酸等；矫味剂包括：甜味剂及各种香精；防腐剂包括：尼泊金类、苯甲酸、苯甲酸钠、山梨酸及其盐类、苯扎溴铵、醋酸氯乙定、桉叶油等；基质包括：PEG6000，PEG4000，虫蜡等。为使上述剂型能够实现中药药剂学，需在制备这些剂型时加入药学可接受的其它辅料(范碧亭《中药药剂学》，上海科学出版社1997年12月第1版中各剂型记载的辅料)。In the application of the present invention, the Chinese medicine composition is one of decoctions, powders, capsules, pills or oral liquid preparations. In order to realize the above dosage forms, it is necessary to add pharmaceutically acceptable adjuvants when preparing these dosage forms, For example: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, etc. Fillers include: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; disintegrants include: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, Cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, croscarmellose sodium, etc.; lubricants include: magnesium stearate, sodium lauryl sulfate, talc, silicon dioxide, etc.; suspending agent Including: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropylmethylcellulose, etc.; binders include starch slurry, polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.; sweeteners include: Sodium saccharin, aspartame, sucrose, cyclamate, glycyrrhetinic acid, etc.; flavoring agents include: sweeteners and various essences; preservatives include: paraben, benzoic acid, sodium benzoate, sorbic acid and other Salts, benzalkonium bromide, chlorhexidine acetate, eucalyptus oil, etc.; substrates include: PEG6000, PEG4000, insect wax, etc. In order to enable the above-mentioned dosage forms to realize Chinese medicine pharmacy, it is necessary to add other pharmaceutically acceptable adjuvants when preparing these dosage forms (Fan Biting "Chinese medicine pharmacy", the adjuvant recorded in each dosage form in the first edition of Shanghai Science Publishing House in December, 1997).
优选的，本发明中药组合物治疗的眩晕症为椎-基底动脉供血不足性眩晕。Preferably, the vertigo treated by the traditional Chinese medicine composition of the present invention is vertigo caused by vertebral-basilar artery insufficiency.
优选的，本发明中药组合物治疗的眩晕症为循环障碍引起的颈性眩晕。Preferably, the vertigo treated by the traditional Chinese medicine composition of the present invention is cervical vertigo caused by circulatory disturbance.
优选的，本发明中药组合物治疗的眩晕症为循环障碍引起的耳源性眩晕。Preferably, the vertigo treated by the traditional Chinese medicine composition of the present invention is otogenic vertigo caused by circulatory disturbance.
经过临床试验表明，给予西比灵胶囊(西安杨森制药有限公司生产)治疗作为对照组，给予本发明药物作为治疗组，对于治疗眩晕症的总有效率为78.50％，明显优于对照组的70.42％，具有显著性差异。Show through clinical test, give Sibeline Capsules (production of Xi'an Janssen Pharmaceutical Co., Ltd.) treatment as matched group, give medicine of the present invention as treatment group, the total effective rate for the treatment of vertigo is 78.50%, obviously better than 70.42% of matched group. %, there is a significant difference.
经过临床试验表明，给予西比灵胶囊(西安杨森制药有限公司生产)治疗作为对照组，给予本发明药物作为治疗组，对于治疗椎-基底动脉供血不足性眩晕的总有效率为83.33％，明显优于对照组的76.92％，具有显著性差异。Show through clinical test, give Sibelin Capsules (production of Xi'an Janssen Pharmaceutical Co., Ltd.) treatment as control group, give medicine of the present invention as treatment group, for the total effective rate of 83.33% for the treatment of vertigo due to vertebral-basilar artery insufficiency, obviously It is better than 76.92% of the control group, with a significant difference.
经过临床试验表明，给予西比灵胶囊(西安杨森制药有限公司生产)治疗作为对照组，给予本发明药物作为治疗组，对于治疗循环障碍引起的颈性眩晕的总有效率为84.76％，明显优于对照组的75.24％，具有显著性差异。Show through clinical test, give Sibelin Capsules (produced by Xi'an Janssen Pharmaceutical Co., Ltd.) treatment as matched group, give medicine of the present invention as treatment group, for the total effective rate of 84.76% for treating the cervical vertigo that circulatory disorder causes, obviously superior to Compared with 75.24% of the control group, there is a significant difference.
经过临床试验表明，给予西比灵胶囊(西安杨森制药有限公司生产)治疗作为对照组，给予本发明药物作为治疗组，对于治疗循环障碍引起的耳源性眩晕的总有效率为83.78％，明显优于对照组的73.35％，具有显著性差异。Show through clinical test, give Sibelin Capsules (production of Xi'an Janssen Pharmaceutical Co., Ltd.) treatment as control group, give medicine of the present invention as treatment group, for the total effective rate of 83.78% for the treatment of otic vertigo caused by circulatory disorder, obviously It is better than 73.35% of the control group, with significant difference.
为证实本发明药物临床疗效，使用按照实施例1所述的方法制备的汤剂(以下称：本发明药物)进行了如下临床观察：For confirming the clinical curative effect of medicine of the present invention, use the decoction (hereinafter referred to as: medicine of the present invention) prepared according to the method described in embodiment 1 to carry out following clinical observation:
1.资料与方法1. Materials and methods
1.1 病例选择1.1 Case selection
参照WHO提出的短暂性椎基底动脉供血不足的诊断标准和国内学者提出的诊断标准(吕冰清，临床神经病学)：Referring to the diagnostic criteria for transient vertebrobasilar insufficiency proposed by WHO and the diagnostic criteria proposed by domestic scholars (Lv Bingqing, Clinical Neurology):
(1)40岁以上发病，有反复发作性眩晕，在头部或体位改变时症状明显或加剧。(1) The onset is over 40 years old, with recurrent vertigo, and the symptoms are obvious or aggravated when the head or body position is changed.
(2)发病急(2分钟内发生)。(2) Acute onset (occurs within 2 minutes).
(3)伴有一种或一种以上椎基底动脉系统缺血发作的症状和体症，如眼震、行走不稳、吞咽困难、构音障碍、听力障碍等，并且经颅多普勒(TCD，以下简称TCD)提示椎基底动脉供血不足。(3) Symptoms and signs accompanied by one or more ischemic attacks of the vertebrobasilar system, such as nystagmus, unsteady walking, dysphagia, dysarthria, hearing impairment, etc., and transcranial Doppler (TCD) , hereinafter referred to as TCD) prompt vertebrobasilar artery insufficiency.
(4)排除其他以眩晕为主要的疾病如耳源性眩晕、小脑或脑干出血或梗塞。(4) Exclude other diseases mainly caused by vertigo, such as ear-originated vertigo, cerebellar or brainstem hemorrhage or infarction.
1.2 一般资料1.2 General information
共观察病例56例，年龄在43-70岁之间，均为我院脑内科住院病人，根据住院先后顺序按照随即数字表分为治疗组和对照组，治疗组30例，男14例，女16例，平均55.18±10.32岁。对照组26例，男12例，女14例，平均55.41±9.68岁。两组性别、发病年龄、病情等资料均无显著性差异(P>0.05)，具有可比性。A total of 56 cases were observed, aged between 43 and 70 years old, all of whom were inpatients in the Department of Brain Medicine of our hospital. They were divided into a treatment group and a control group according to the order of hospitalization according to the random number table. There were 30 cases in the treatment group, 14 cases were male and 14 were female. 16 cases, with an average age of 55.18±10.32. The control group included 26 cases, including 12 males and 14 females, with an average age of 55.41±9.68. There was no significant difference in gender, age of onset, disease condition and other data between the two groups (P>0.05), which were comparable.
1.3 治疗方法1.3 Treatment methods
1.3.1 治疗组取本发明药物的汤剂400ml，早、晚两次分服，疗程2周。1.3.1 The treatment group took 400ml of decoction of the medicine of the present invention, and took it twice in the morning and evening, and the course of treatment was 2 weeks.
1.3.2 对照组给予西比灵胶囊(西安杨森制药有限公司生产)，每次5mg，每晚1次口服，疗程2周。1.3.2 The control group was given Sibeline Capsules (manufactured by Xi’an Janssen Pharmaceutical Co., Ltd.), 5 mg each time, orally once a night, and the course of treatment was 2 weeks.
1.4 观察方法1.4 Observation method
观察两组治疗前后主要症状(眩晕，头痛，恶心，呕吐，耳鸣，视物旋转不清楚，复视或四肢、面部麻木，颈项不适疼痛)的变化，并记录眩晕程度、持续时间以及治疗前后TCD的变化。Observe the changes of main symptoms (vertigo, headache, nausea, vomiting, tinnitus, unclear rotation of vision, diplopia or numbness of limbs and face, neck discomfort and pain) in the two groups before and after treatment, and record the degree of vertigo, duration and TCD before and after treatment. The change.
1.5 疗效标准1.5 Efficacy Standards
参照《中医病证诊断疗效标准》。根据眩晕缓解程度分3级Refer to "Diagnosis and Curative Effect Criteria of TCM Syndrome". According to the degree of dizziness relief, it is divided into 3 levels
(1)痊愈：变换头位时无视物旋转或晃动，伴随症状消失；TCD血流速度正常。(1) Recovery: When the head position is changed, the object rotates or shakes regardless, and the accompanying symptoms disappear; the blood flow velocity of TCD is normal.
(2)好转：静止时无视物旋转或晃动，但变换头位时可诱发且存在部分伴随症状，TCD血流速度改善50％以上。(2) Improvement: The rotation or shaking of the object is ignored at rest, but it can be induced when the head position is changed and there are some accompanying symptoms, and the blood flow velocity of TCD is improved by more than 50%.
(3)无效：眩晕及伴随症状无改善，TCD血流速度改善50％以下。(3) Ineffective: dizziness and accompanying symptoms did not improve, and TCD blood flow velocity improved by less than 50%.
1.6 统计学方法：1.6 Statistical methods:
计量资料用(x±s)表示，采用t检验，计数资料采用Ridit检验。The measurement data are represented by (x±s), and the t test is used, and the enumeration data are used Ridit test.
2.结果2. Results
2.1 两组临床疗效比较(表1)2.1 Comparison of clinical efficacy between the two groups (Table 1)
表1 两组临床疗效比较(例)Table 1 Comparison of clinical efficacy between the two groups (example)
与对照组比较*p<0.05Compared with the control group * p<0.05
结果显示治疗组临床疗效明显优于对照组(P<0.05)，且眩晕消失时间短于对照组(P<0.05)。The results showed that the clinical curative effect of the treatment group was significantly better than that of the control group (P<0.05), and the vertigo disappearing time was shorter than that of the control group (P<0.05).
2.2 两组椎-基底动脉平均血流速度变化比较(表2)2.2 Comparison of changes in mean blood flow velocity of the vertebral-basilar artery between the two groups (Table 2)
表2 两组椎-基底动脉平均血流速度变化比较(x±s)Table 2 Comparison of changes in mean blood flow velocity of the vertebral-basilar artery between the two groups (x±s)
与治疗前比较：*p<0.05，与对照组治疗后比较：ΔP<0.05Compared with before treatment: * p<0.05, compared with the control group after treatment: ΔP<0.05
两组治疗前椎-基底动脉供血平均流速比较，差异均无显著性意义(P>0.05)，两组治疗后各指标比较，差异均有显著性意义(P<0.05)。There was no significant difference in the average flow rate of vertebral-basilar artery blood supply between the two groups before treatment (P>0.05), but there were significant differences in each index between the two groups after treatment (P<0.05).
3、结论3. Conclusion
以上临床研究表明，本发明药物可消除或减轻患者症状，并有改善椎-基底动脉血流速度等作用，是治疗椎-基底动脉供血不足性眩晕的有效药物。The above clinical studies show that the medicine of the present invention can eliminate or alleviate the patient's symptoms, and has the effects of improving the blood flow velocity of the vertebral-basilar artery, etc., and is an effective medicine for treating vertigo caused by vertebral-basilar artery insufficiency.
具体实施方式 Detailed ways
下面结合本发明药物汤剂、散剂、胶囊剂、丸剂和口服液的制备的实例，说明本发明的具体实施方式。The specific embodiment of the present invention will be described below in conjunction with the examples of the preparation of medicinal decoction, powder, capsule, pill and oral liquid of the present invention.
实施例1：Example 1:
黄芪 32克 水蛭 2.5克 全蝎 2.5克 川芎 7克Astragalus 32g Leech 2.5g Scorpion 2.5g Chuanxiong 7g
山茱萸 7克 怀牛膝 7克 白术 7克 茯苓 15克Cornus officinalis 7 grams Achyranthes bidentata 7 grams Atractylodes macrocephala 7 grams Poria cocos 15 grams
陈皮 6.5克 竹茹 6.5克 当归 7克 石菖蒲 6克Chenpi 6.5g Bamboo Ru 6.5g Angelica 7g Shichangpu 6g
制备方法：按常规制剂方法制成汤剂。Preparation method: make decoction according to conventional preparation method.
实施例2：Example 2:
黄芪 48克 水蛭 4.5克 全蝎 4.5克 川芎 11克Astragalus 48g Leech 4.5g Scorpio 4.5g Chuanxiong 11g
山茱萸 11克 怀牛膝 14克 白术 14克 茯苓 38克Cornus officinalis 11g Achyranthes bidentata 14g Atractylodes macrocephala 14g Poria cocos 38g
陈皮 10.5克 竹茹 11.5克 当归 13.5克 石菖蒲 9克Chenpi 10.5g Bamboo Ru 11.5g Angelica 13.5g Shichangpu 9g
制备方法：按常规制剂方法制成散剂。Preparation method: make powder according to conventional preparation methods.
实施例3：Example 3:
黄芪 34克 水蛭 5克 全蝎 2.5克 川芎 11.5克Astragalus 34g Leech 5g Scorpio 2.5g Chuanxiong 11.5g
山茱萸 6.5克 怀牛膝 14克 白术 7克 茯苓 37克Cornus officinalis 6.5 grams Achyranthes bidentata 14 grams Atractylodes macrocephala 7 grams Poria cocos 37 grams
陈皮 6.5克 竹茹 11克 当归 7克 石菖蒲 8.5克Chenpi 6.5g Bamboo Ru 11g Angelica 7g Shichangpu 8.5g
制备方法：按常规制剂方法制成胶囊剂。Preparation method: make capsules according to conventional preparation methods.
实施例4：Example 4:
黄芪 40克 水蛭 3.5克 全蝎 3.5克 川芎 9克Astragalus 40g Leech 3.5g Scorpion 3.5g Chuanxiong 9g
山茱萸 9克 怀牛膝 10.5克 白术 10克 茯苓 25克Cornus officinalis 9 grams Achyranthes bidentata 10.5 grams Atractylodes macrocephala 10 grams Poria cocos 25 grams
陈皮 9克 竹茹 9克 当归 10.5克 石菖蒲 7.5克Chenpi 9g Bamboo Ru 9g Angelica 10.5g Shichangpu 7.5g
制备方法：按常规制剂方法制成丸剂。Preparation method: make pills according to conventional preparation methods.
实施例5：Example 5:
黄芪 48克 水蛭 2.5克 全蝎 4.5克 川芎 7克Astragalus 48g Leech 2.5g Scorpion 4.5g Chuanxiong 7g
山茱萸 11克 怀牛膝 7克 白术 14克 茯苓 15克Cornus officinalis 11g Achyranthes bidentata 7g Atractylodes macrocephala 14g Poria cocos 15g
陈皮 10克 竹茹 7克 当归 13克 石菖蒲 5.5克Chenpi 10g Bamboo Ru 7g Angelica 13g Shichangpu 5.5g
制备方法：按常规制剂方法制成口服液。Preparation method: make oral liquid according to conventional preparation methods.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101632070A CN101411829A (en) | 2007-10-19 | 2007-10-19 | Chinese medicinal composition for treating megrims and formulation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101632070A CN101411829A (en) | 2007-10-19 | 2007-10-19 | Chinese medicinal composition for treating megrims and formulation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101411829A true CN101411829A (en) | 2009-04-22 |
Family
ID=40592707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101632070A Pending CN101411829A (en) | 2007-10-19 | 2007-10-19 | Chinese medicinal composition for treating megrims and formulation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101411829A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869674A (en) * | 2010-06-01 | 2010-10-27 | 张晓玲 | Chinese medicinal composition for treating vertigo |
| CN102772675A (en) * | 2012-07-24 | 2012-11-14 | 重庆希尔安药业有限公司 | Pharmaceutical composition for treating apoplexy hemiplegia and preparation method of pharmaceutical composition |
| CN102772676A (en) * | 2012-08-20 | 2012-11-14 | 解连新 | Traditional Chinese medicine for treating empirical vertigo |
| CN104887964A (en) * | 2015-06-02 | 2015-09-09 | 张永伟 | Traditional Chinese medicine for treating phlegm-accumulation vein-resistance type vertigo and preparation method of traditional Chinese medicine |
| CN107019768A (en) * | 2017-05-28 | 2017-08-08 | 成都风靡生物科技有限公司 | It is a kind of effectively to treat capsule medicine of vertigo and preparation method thereof |
| CN108434385A (en) * | 2018-05-18 | 2018-08-24 | 重庆跃龙生物制药有限公司 | Chinese medicine composition and preparation method thereof for treating vertigo |
-
2007
- 2007-10-19 CN CNA2007101632070A patent/CN101411829A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869674A (en) * | 2010-06-01 | 2010-10-27 | 张晓玲 | Chinese medicinal composition for treating vertigo |
| CN101869674B (en) * | 2010-06-01 | 2012-07-04 | 张晓玲 | Chinese medicinal composition for treating vertigo |
| CN102772675A (en) * | 2012-07-24 | 2012-11-14 | 重庆希尔安药业有限公司 | Pharmaceutical composition for treating apoplexy hemiplegia and preparation method of pharmaceutical composition |
| CN102772675B (en) * | 2012-07-24 | 2013-12-11 | 重庆希尔安药业有限公司 | Pharmaceutical composition for treating apoplexy hemiplegia and preparation method of pharmaceutical composition |
| CN102772676A (en) * | 2012-08-20 | 2012-11-14 | 解连新 | Traditional Chinese medicine for treating empirical vertigo |
| CN102772676B (en) * | 2012-08-20 | 2014-04-16 | 济南伟传信息技术有限公司 | Traditional Chinese medicine for treating empirical vertigo |
| CN104887964A (en) * | 2015-06-02 | 2015-09-09 | 张永伟 | Traditional Chinese medicine for treating phlegm-accumulation vein-resistance type vertigo and preparation method of traditional Chinese medicine |
| CN107019768A (en) * | 2017-05-28 | 2017-08-08 | 成都风靡生物科技有限公司 | It is a kind of effectively to treat capsule medicine of vertigo and preparation method thereof |
| CN108434385A (en) * | 2018-05-18 | 2018-08-24 | 重庆跃龙生物制药有限公司 | Chinese medicine composition and preparation method thereof for treating vertigo |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Markman et al. | Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. | |
| CN101411829A (en) | Chinese medicinal composition for treating megrims and formulation thereof | |
| Storms et al. | Effectiveness of azelastine nasal solution in seasonal allergic rhinitis | |
| WO2016107579A1 (en) | Preparation and application of flavonol as brain-targeting synergist | |
| CN102210844A (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN111840456A (en) | Traditional Chinese medicine composition for treating respiratory diseases | |
| CN108125940B (en) | Application of valeric acid in preparation of medicine for preventing and/or treating side effect of tumor radiotherapy | |
| CN101406613B (en) | Use of Chinese medicinal composition in preparing medicament for treating vital myocarditis | |
| CN103055112B (en) | Traditional Chinese medicine compound composition for treating uveitis | |
| TWI720396B (en) | Use of Pien Tze Huang and its preparations in treating neuralgia after herpes zoster | |
| CN110856741A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating diarrhea | |
| CN107519176A (en) | Prevent and treat motion sickness, the medicine of Meniere disease and the medical usage of mozavaptan | |
| CN108465061A (en) | It is a kind of to be used to treat pharmaceutical composition of Facial Recurrent Dermatitis and its preparation method and application | |
| WO2006094460A1 (en) | A medicine for treating cough and asthma and preparation method thereof | |
| CN111821375B (en) | Application of a traditional Chinese medicine composition in preparation of medicine for treating dementia | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| Cullis et al. | Vidarabine encephalopathy. | |
| CN108403764B (en) | A kind of external preparation for treating facial recurrent dermatitis and preparation method | |
| CN102309675B (en) | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome | |
| CN101559161A (en) | Application of traditional Chinese medicine composition in preparing medicament for curing tristimania | |
| Hurley et al. | Localized pityriasis rosea | |
| AU2019201371B2 (en) | Composition of combined plant proteins for treatment of cancer and diabetes | |
| CN113288895A (en) | Medicine for treating meniere disease and application thereof | |
| WO2008154794A1 (en) | The use of an extract of salvia miltiorrhiza for manufacture of a medicament for treatment of septicemia | |
| CN121102367A (en) | A traditional Chinese medicine composition with the function of softening hard masses and promoting blood circulation, its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090422 |